Gene delivery articles from across Nature Portfolio

Nucleic acid-based therapies offer an alternative to traditional cancer treatment modalities, with promising data beginning to emerge. In this Review, the authors describe the design and development of nucleic acid-based therapies administered virally and non-virally, including discussions of the advantages and disadvantage of each approach, as well as the role of patient-specific factors such as the tumour microenvironment, and consider the most promising future research directions.

A biodegradable electronic bandage that applies pulsed and d.c. electrostimulation can accelerate the healing of intestinal wounds in mice via transfection of cells and stimulation-induced secretion of healing factor from those cells.

Systemic Lupus Erythematosus (SLE) is a chronic and progressive autoimmune disease characterized by abnormally activated B cells causing organ damage. Here authors introduce an adoptive cell therapy involving regulatory T cells overexpressing FoxP3 and harboring an anti-CD19 CAR to inhibit pathological B cells and thus tissue-harming autoimmunity in a humanized mouse model.

A study in Nature Biotechnology reports a platform that combines lentivirus capabilities with antibody recognition for targeted cell delivery and genome editing.

Prime editing in vivo is systematically improved with an eye to clinical translation.

Many genetic therapies are limited by a lack of methods for delivering them to target cells in the body. We have developed technologies to engineer biological nanovesicles to load therapeutic proteins, target recipient immune cells and deliver Cas9 to knock out CXCR4 in primary human T cells.

Arrhythmogenic cardiomyopathy is a major cause of sudden death among young people. Three studies show that gene therapy to restore the desmosomal protein PKP2 holds promise in improving the prognosis of affected individuals.

A study of AAV gene therapy in monkeys proposes that integrated vectors may drive long-term transgene expression.